BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27989785)

  • 21. Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.
    Osman WM; Youssef NS
    Int J Clin Exp Pathol; 2015; 8(7):8165-77. PubMed ID: 26339385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in a prospective series of papillary renal cell carcinoma.
    Gontero P; Ceratti G; Guglielmetti S; Andorno A; Terrone C; Bonvini D; Faggiano F; Tizzani A; Frea B; Valente G
    BJU Int; 2008 Sep; 102(6):697-702. PubMed ID: 18489525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
    Terakawa T; Miyake H; Kusuda Y; Fujisawa M
    Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma.
    Chen L; Shi Y; Jiang CY; Wei LX; Lv YL; Wang YL; Dai GH
    Int J Biol Markers; 2011; 26(2):108-16. PubMed ID: 21574155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens.
    Minardi D; Lucarini G; Mazzucchelli R; Milanese G; Natali D; Galosi AB; Montironi R; Biagini G; Muzzonigro G
    J Urol; 2005 Oct; 174(4 Pt 1):1208-12. PubMed ID: 16145371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients.
    Charpidou A; Gkiozos I; Konstantinou M; Eleftheraki A; Demertzis P; Harrington K; Polyzos A; Syrigos KN
    Cancer Lett; 2011 May; 304(2):144-53. PubMed ID: 21396771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of insulin- like growth factor-I receptor expression in renal cell carcinoma.
    Sichani MM; Yazdi FS; Moghaddam NA; Chehrei A; Kabiri M; Naeimi A; Taheri D
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):69-74. PubMed ID: 20061696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
    An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
    Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma.
    Kerr DA; Busarla SVP; Gimbel DC; Sohani AR; Nazarian RM
    Hum Pathol; 2017 Jul; 65():157-165. PubMed ID: 28506734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of intratumoral C-reactive protein expression in patients with clear cell renal cell carcinoma.
    Can C; Acikalin MF; Ozen A; Dundar E
    Urol Int; 2014; 92(3):270-5. PubMed ID: 24356040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
    Klatte T; Böhm M; Nelius T; Filleur S; Reiher F; Allhoff EP
    BJU Int; 2007 Jul; 100(1):209-14. PubMed ID: 17428240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low differentiated microvascular density and low expression of platelet-derived growth factor-BB (PDGF-BB) predict distant metastasis and poor prognosis in clear cell renal cell carcinoma.
    Qi L; Du J; Zhang Z; Diao L; Chen X; Yao X
    BJU Int; 2013 Aug; 112(4):E415-23. PubMed ID: 23879920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
    Mele T; Generali D; Fox S; Brizzi MP; Bersiga A; Milani M; Allevi G; Bonardi S; Aguggini S; Volante M; Dogliotti L; Bottini A; Harris A; Berruti A
    Breast Cancer Res Treat; 2010 Oct; 123(3):795-804. PubMed ID: 20680681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
    Klatte T; Pantuck AJ; Said JW; Seligson DB; Rao NP; LaRochelle JC; Shuch B; Zisman A; Kabbinavar FF; Belldegrun AS
    Clin Cancer Res; 2009 Feb; 15(4):1162-9. PubMed ID: 19228721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.